Corcept Therapeutics Incorporated has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for relacorilant as a treatment for patients with platinum-resistant ovarian cancer. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026, for the application. This NDA submission is based on positive results from Corcept's Phase 3 ROSELLA and Phase 2 trials, which showed that patients receiving relacorilant in combination with nab-paclitaxel experienced improved progression-free and overall survival compared to those receiving nab-paclitaxel alone. The treatment was well-tolerated, without increasing patients' safety burden. This regulatory review brings Corcept closer to providing a new treatment option for this challenging form of ovarian cancer.